Renal Cell Carcinoma

This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Head & Neck

Hodgkin Lymphoma

THE FIRST AND ONLY DUAL IMMUNOTHERAPY IN 1L aRCC

View indication details

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.
OPDIVO in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Expert opinion

CheckMate 214
8-year update

A library of patient
cases treated with
OPDIVO+YERVOY in 1L RCC

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing schemes
in aRCC

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

A diary for your patients
treated with OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient brochure
with practical information
on immunotherapy

Patient alert card
OPDIVO

Useful links

ImmunoScience Academy
An educational multi-disciplinary platform on immunology and immunotherapy

BSMO immunomanager Comprehensive recommendations
on the diagnostic algorithm and treatment of different types of irAE

Belgian Multidisciplinary Immunotoxicity Board (BITOX) Submit your case/questions
about irAEs

BSP poster
PD-L1 testing
accross tumor indications

1L aRCC, first-line advanced renal cell carcinoma irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.